Cutaneous T-Cell Lymphoma – Drugs In Development, 2023
Powered by
Unlock hidden opportunities in the Pharmaceuticals industry
Global Markets Direct’s, ‘Cutaneous T-Cell Lymphoma – Drugs In Development, 2023’, provides an overview of the Cutaneous T-Cell Lymphoma pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Cutaneous T-Cell Lymphoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Cutaneous T-Cell Lymphoma and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note:
*Certain sections in the report may be removed or altered based on the availability and relevance of data.
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase
* Global Markets Direct, is a research brand owned and operated by GlobalData.
Scope
- The report provides a snapshot of the global therapeutic landscape of Cutaneous T-Cell Lymphoma
- The report reviews pipeline therapeutics for Cutaneous T-Cell Lymphoma by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Cutaneous T-Cell Lymphoma therapeutics and enlists all their major and minor projects
- The report assesses Cutaneous T-Cell Lymphoma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Cutaneous T-Cell Lymphoma
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Cutaneous T-Cell Lymphoma
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Cutaneous T-Cell Lymphoma pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Key Players
4SC AGAB Science SA
AbbVie Inc
Affimed GmbH
Amgen Inc
Angel Pharmaceuticals Inc
Ascentage Pharma Group International
Astex Pharmaceuticals Inc
AstraZeneca Plc
Baylor College of Medicine
Beijing Boren Hospital
Bio-Path Holdings Inc
BioInvent International AB
BioXpress Therapeutics SA
Boston Immune Technologies and Therapeutics Inc
Bristol-Myers Squibb Co
Cartherics Pty Ltd
Celdara Medical LLC
Celldex Therapeutics Inc
CerRx Inc
Citius Pharmaceuticals Inc
CRISPR Therapeutics AG
CSPC Pharmaceutical Group Ltd
CTI BioPharma Corp
Curis Inc
Curon Biopharmaceutical Ltd
Cyclacel Pharmaceuticals Inc
CytomX Therapeutics Inc
Daiichi Sankyo Co Ltd
Dizal Pharmaceutical Co Ltd
Equillium Inc
F. Hoffmann-La Roche Ltd
Fresh Tracks Therapeutics Inc
Galderma SA
Genexine Inc
Helsinn Healthcare SA
iCell Gene Therapeutics LLC
Innate Pharma SA
Kymera Therapeutics Inc
Kyowa Kirin Co Ltd
March Biosciences
Massachusetts General Hospital
MedC Biopharma Ltd
Medivir AB
Merck & Co Inc
Merck KGaA
Micreos BV
Moleculin Biotech Inc
MorphoSys AG
Mundipharma EDO GmbH
National Cancer Institute US
NAYA Biosciences Inc
Neonc Technologies Inc
Onco Therapies Inc
OncoVerity Inc
Oncovir Inc
Ono Pharmaceutical Co Ltd
Pfizer Inc
Philogen SpA
Prescient Therapeutics Ltd
Relief Therapeutics Holding AG
Revolution Medicines Inc
Rhizen Pharmaceuticals SA
Rock Immune LLC
Sanofi
SciTech Development LLC
Seagen Inc
Secura Bio Inc
selectION Inc
Shanghai Pharmaceuticals Holding Co Ltd
Shenzhen Chipscreen Biosciences Co Ltd
Simcere Pharmaceutical Group Ltd
SIRPant Immunotherapeutics Inc
Soligenix Inc
Sonoval LLC
Sorrento Therapeutics Inc
Step Pharma
Taiwan Liposome Co Ltd
Takeda Pharmaceutical Co Ltd
Torqur AG
University of Cologne
Vidac Pharma
Viracta Therapeutics Inc
Vyriad Inc
West Lake Biomedical Technology (Hangzhou) Co Ltd
Wugen Inc
Wuhan Bio-Raid Biotechnology Co Ltd
Wuxi People’s Hospital
Yakult Honsha Co Ltd
Zhejiang Borui Biopharmaceutical Co Ltd